Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration

Journal of Neuroscience

Volumn 36, Issue 18, 2016, Pages 5144-5159

  Qin, Hongwei ^a   Buckley, Jessica A ^a   Li, Xinru ^a   Liu, Yudong ^a   Fox, Thomas H ^a   Meares, Gordon P ^a   Yu, Hao ^a   Yan, Zhaoqi ^a   Harms, Ashley S ^a   Li, Yufeng ^b   Standaert, David G ^a   Benveniste, Etty N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

JAK STAT pathway; JAKinibs; Neurodegeneration; Neuroinflammation; Parkinson s disease; synuclein

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ALPHA SYNUCLEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; JANUS KINASE; NEUROPROTECTIVE AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; INFLAMMATION; MACROPHAGE; MICROGLIA; MOUSE; NEURODEGENERATIVE DISEASES; PATHOLOGY; SPRAGUE DAWLEY RAT;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINERGIC NEURONS; INFLAMMATION; JANUS KINASES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STAT TRANSCRIPTION FACTORS;

EID: 84965046341     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4658-15.2016     Document Type: Article

References (80)

1. Adamski J, Benveniste EN (2005) 17beta-estradiol activation of the c-Jun N-terminal kinase pathway leads to down-regulation of class II major histocompatibility complex expression. Mol Endocrinol 19:113-124. CrossRef Medline
2. Allen Reish HE, Standaert DG (2015) Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 5:1-19. CrossRef Medline
3. Appel SH, Beers DR, Henkel JS (2010) T cell-microglial dialogue in Parkinson’s disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 31:7-17. CrossRef Medline
4. Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-RamosM (2012) Longterm polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 208:85-96. CrossRef Medline
5. Benveniste EN, Liu Y, McFarland BC, Qin H (2014) Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res 34:577-588. CrossRef Medline
6. Béraud D, Maguire-Zeiss KA (2012) Misfolded alpha-synuclein and tolllike receptors: therapeutic targets for Parkinson’s disease. Parkinsonism Relat Disord 18:S17-S20. CrossRef Medline
7. Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol 2012:845618. CrossRef Medline
8. Brochard V, Combadiére B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192. CrossRef Medline
9. Cao S, Theodore S, Standaert DG (2010) Fcδ receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson’s disease. Mol Neurodegener 5:42. CrossRef Medline
10. Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, Kanter E, Budhu S, Mandelbaum J, Vonsattel JP, Zecca L, Loike JD, Sulzer D (2014) MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 5:3633-3648. CrossRef Medline
11. Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, Golde TE (2011) Interferongamma induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci 14:694-696. CrossRef Medline
12. Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol 167:90-95. CrossRef Medline
13. Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB (2014) Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A 111:9289-9294. CrossRef Medline
14. Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA (2015) Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci Signal 8:ra45. CrossRef Medline
15. Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A (2012) Progressive neurodegenerative and behavioural changes induced by AAVmediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45:939-953. CrossRef Medline
16. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545-558. CrossRef Medline
17. Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36:180-190. CrossRef Medline
18. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N (2013) Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61:349-360. CrossRef Medline
19. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, Popovich PG, Guttridge DC, Kaspar BK (2014) Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron 81:1009-1023. CrossRef Medline
20. Funk N, Wieghofer P, Grimm S, Schaefer R, Bühring HJ, Gasser T, Biskup S (2013) Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson’s disease. Mov Disord 28:392-395. CrossRef Medline
21. Gahmberg CG, Ning L, Paetau S (2014) ICAM-5: a neuronal dendritic adhesion molecule involved in immune and neuronal functions. Adv Neurobiol 8:117-132. CrossRef Medline
22. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ (2010) Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10:453-460. CrossRef Medline
23. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 104:18754-18759. CrossRef Medline
24. González H, Contreras F, Pacheco R (2015) Regulation of the neurodegenerative process associated to Parkinson’s disease by CD4+ T cells. J Neuroimmune Pharmacol 10:561-575. CrossRef Medline
25. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, MuzyczkaN (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105:763-768. CrossRef Medline
26. Gray GK, McFarland BC, Nozell SE, Benveniste EN (2014) NF-kappaB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother 14:1293-1306. CrossRef Medline
27. Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A, Hengerer B, Kassubek J, Ludolph AC, Weishaupt JH, Danzer KM (2014) Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients. Acta Neuropathol 128:651-663. CrossRef Medline
28. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, PayamiH (2010) Com-mon genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781-785. CrossRef Medline
29. Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG (2013) MHCII is required for α-Synucleininduced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33:9592-9600. CrossRef Medline
30. Hawthorne AL, Popovich PG (2011) Emerging concepts in myeloid cell biology after spinal cord injury. Neurotherapeutics 8:252-261. CrossRef Medline
31. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497. CrossRef Medline
32. Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18:S210-212. CrossRef Medline
33. Hu X, Ivashkiv LB (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31:539-550. CrossRef Medline
34. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, Haroutunian V, Zhu J, Donovan MJ, Sharp AJ, Casaccia P (2014) Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci 17:121-130. CrossRef Medline
35. Irwin DJ, Lee VM, Trojanowski JQ (2013) Parkinson’s disease dementia:convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14:626-636. CrossRef Medline
36. Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36-49. CrossRef Medline
37. Kannarkat GT, Boss JM, TanseyMG (2013) The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis 3:493-514. CrossRef Medline
38. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29:13435-13444. CrossRef Medline
39. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ (2013) Neuron-released oligomeric alphasynuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4:1562-1586. CrossRef Medline
40. Kontzias A, Kotlyar A, Laurence A, Changelian P, O’Shea JJ (2012) Jakinibs:a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464-470. CrossRef Medline
41. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M, Udalova IA (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12:231-238. CrossRef Medline
42. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ (2010) Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262-9272. CrossRef Medline
43. Lee HJ, Bae EJ, Lee SJ (2014) Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10:92-98. CrossRef Medline
44. Lee YJ, Benveniste EN (1996) STAT-1alpha expression is involved in IFNgamma induction of the class II transactivator and class II MHC genes. J Immunol 157:1559-1568. Medline
45. Liu Y, Holdbrooks AT, De Sarno P, Rowse AL, Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S, Benveniste EN, Qin H (2014) Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol 192:59-72. CrossRef Medline
46. Liu Y, Holdbrooks AT, Meares GP, Buckley JA, Benveniste EN, QinH (2015) Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotype. J Immunol 195:841-852. CrossRef Medline
47. Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13. CrossRef Medline
48. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN (2011) Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10:2384-2393. CrossRef Medline
49. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285-1291. CrossRef Medline
50. Moehle MS, West AB (2015) M1 and M2 immune activation in Parkinson’s disease: foe and ally? Neuroscience 302:59-73. CrossRef Medline
51. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32:1602-1611. CrossRef Medline
52. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009381. CrossRef Medline
53. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328-3337. CrossRef Medline
54. Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JP (1999) Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J Neuroimmunol 99:195-204. CrossRef Medline
55. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A (2013) Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3:1393-1398. CrossRef Medline
56. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16:653-661. CrossRef Medline
57. Olson KE, Kosloski-Bilek LM, Anderson KM, Diggs BJ, Clark BE, Gledhill JM Jr, Shandler SJ, Mosley RL, Gendelman HE (2015) Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice. J Neurosci 35:16463-16478. CrossRef Medline
58. O’Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542-550. CrossRef Medline
59. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311-328. CrossRef Medline
60. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alphasynuclein gene identified in families with Parkinson’s disease. Science 276:2045-2047. CrossRef Medline
61. Qin H, Wilson CA, Lee SJ, Benveniste EN (2006) IFN-β induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J 20:985-987. CrossRef Medline
62. Qin H, Yeh WI, De Sarno P, Holdbrooks AT, Liu Y, Muldowney MT, Reynolds SL, Yanagisawa LL, Fox TH 3rd, Park K, Harrington LE, Raman C, Benveniste EN (2012) Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc Natl Acad Sci U S A 109:5004-5009. CrossRef Medline
63. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, Imboywa S, Von Korff A, Okada Y, Patsopoulos NA, Davis S, McCabe C, Paik HI, Srivastava GP, Raychaudhuri S, Hafler DA, et al. (2014) Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:519-523. CrossRef Medline
64. Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P (2008) Generation of a alpha-synuclein-based rat model of Parkinson’s disease. Neurobiol Dis 30:8-18. CrossRef Medline
65. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE (2010) Regulatory T cells attenuate TH17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184:2261-2271. CrossRef Medline
66. Romero-Ramos M, von Euler Chelpin M, Sanchez-Guajardo V (2014) Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother 10:852-867. CrossRef Medline
67. Roodveldt C, Christodoulou J, DobsonCM (2008) Immunological features of alpha-synuclein in Parkinson’s disease. J Cell Mol Med 12:1820-1829. CrossRef Medline
68. Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M (2013) α-Synuclein vaccination prevents the accumulation of parkinson diseaselike pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol 72:624-645. CrossRef Medline
69. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M (2015) The relation between alpha-synuclein and microglia in Parkinson’s disease: recent developments. Neuroscience 302:47-58. CrossRef Medline
70. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, GendelmanHE (2012) CD4+regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmune Pharmacol 7:927-938. CrossRef Medline
71. Sherer TB (2011) Biomarkers for Parkinson’s disease. Sci Transl Med 3:79ps14. CrossRef Medline
72. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, et al. (2003) α-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. CrossRef Medline
73. Tang Y, Le W (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181-1194. CrossRef Medline
74. Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67:1149-1158. CrossRef Medline
75. Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, Kuypers DR, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt V (2015) FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson’s disease. Neurobiol Aging 36:1559-1568. CrossRef Medline
76. Van Wagoner NJ, O’Keefe GM, Benveniste EN (1998) Kinase inhibitors abrogate IFN-δ-induced class II transactivator and class II MHC gene expression in astroglioma cell lines. J Neuroimmunol 85:174-185. CrossRef Medline
77. Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ (2015) Mechanisms of JAK/STAT signaling in immunity and disease. J Immunol 194:21-27. CrossRef Medline
78. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57-63. CrossRef Medline
79. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu Rev Immunol 25:821-852. CrossRef Medline
80. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19:533-542. CrossRef Medline